# EDGAR Filing Document

**Accession Number:** 0001213809
**File Stem:** 0001493152-25-017306
**Filing Date:** 2025-10
**Character Count:** 13394
**Document Hash:** 0f222f09721dc9381cc55e4e8d2f4fbc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-017306.hdr.sgml**: 20251007

**ACCESSION NUMBER**: 0001493152-25-017306

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251006

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251007

**DATE AS OF CHANGE**: 20251007

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DYADIC INTERNATIONAL INC
- **CENTRAL INDEX KEY:** 0001213809
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 450486747
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32513
- **FILM NUMBER:** 251380317

**BUSINESS ADDRESS:**
- **STREET 1:** 1044 NORTH U.S. HIGHWAY ONE
- **STREET 2:** SUITE 201
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477
- **BUSINESS PHONE:** 561-743-8333

**MAIL ADDRESS:**
- **STREET 1:** 1044 NORTH U.S. HIGHWAY ONE
- **STREET 2:** SUITE 201
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CCP WORLDWIDE INC
- **DATE OF NAME CHANGE:** 20030110

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): <u>October 6, 2025</u>**

**Dyadic International, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-32513** | **45-0486747** |
| (State or other jurisdiction | (Commission | (I.R.S. Employer |
| of incorporation or organization) | File Number) | Identification Number) |

---

**1044 North U.S. Highway One, Suite 201**

**Jupiter, FL 33477**

(Address of principal executive offices and zip code)

(561) 743-8333

(Registrant's telephone number, including area code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | DYAI | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01. Regulation FD Disclosure.**

On October 6, 2025, Dyadic International, Inc. (the "Company") issued a press release announcing the Company's recent milestone achievements and other business developments. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 8.01. Other Events.**

As previously disclosed, on June 23, 2025, the Company received a deficiency notice from the staff of the Nasdaq Listing Qualifications department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had failed to maintain a minimum market value of listed securities of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2), and providing a grace period until December 20, 2025 to regain compliance. Additionally, as previously disclosed, on July 17, 2025, the Company received a deficiency notice from the Staff of Nasdaq notifying the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2), and providing a grace period until January 13, 2026 (subject to an additional extension period depending on circumstances) to regain compliance.

At the beginning of October 2025, the Company was notified that it has regained compliance with all such requirements for continued listing on the Nasdaq Capital Market, and that the above-mentioned deficiency matters are now closed. On October 1, 2025, the Company received a letter from the Staff notifying the Company that the Staff had determined that for the last 10 consecutive business days, from September 16, 2025 to September 30, 2025, the Company's market value of listed securities was $35 million or greater, and accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(b)(2). On October 3, 2025, the Company received a letter from the Staff notifying the Company that the Staff had determined that for the last 10 consecutive business days, from September 19, 2025 to October 2, 2025, the closing bid price of the Company's common stock was $1.00 per share or greater, and accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits:

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 99.1 | [Dyadic International, Inc. Press Release Dated October 6, 2025](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: October 7, 2025 |  |  |
|  | DYADIC INTERNATIONAL, INC. | DYADIC INTERNATIONAL, INC. |
|  | **By:** | */s/ Ping W. Rawson* |
|  |  | **Ping W. Rawson** |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments**

**JUPITER, Fla., October 6, 2025 (GLOBE NEWSWIRE)** —Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications today announced the achievement of additional milestone payments in its collaborations with Proliant Health & Biologicals in life sciences and Inzymes ApS in food and nutrition, along with updates on its business transformation and commercial progress.

"Dyadic is advancing its transition to a commercially focused, revenue-driven company, said Joe Hazelton, Dyadic Applied BioSolutions President and Chief Operating Officer. "The third quarter featured substantial progress throughout our portfolio, marked by notable achievements in partnerships with Proliant Health and Biologicals in the life sciences sector, as well as ongoing collaborations with Inzymes in food and nutrition. These accomplishments highlight the versatility and scalability of Dyadic's protein production platforms across multiple markets. The company remains committed to capitalizing on near-term commercialization opportunities, supported by a stronger balance sheet and an expanding pipeline of both partner-led and internally developed products".

**Recent Company Developments**

**Life Sciences**

● **Recombinant Human Albumin (Proliant Partnership):** In Q3 2025, Dyadic reached a milestone in productivity, achieving a $500,000 milestone, with payment anticipated in Q4 2025. Additional revenue growth is expected as commercialization advances. Proliant has started sampling the product, with the commercial launch targeted for late 2025 and early 2026.

● **Recombinant Transferrin:** Sampling efforts are expanding in research, diagnostic and cultured meat markets. Initial production of lab-grade non-animal transferrin products is underway to meet current OEM and supply opportunities. Validation is ongoing with research and diagnostic customers.

● **Recombinant DNase I (RNase-free):** Dyadic's DNase I has successfully met required performance benchmarks for activity and purity, validating its utility in molecular biology, diagnostics, and biopharma applications. Dyadic is currently producing its DNase I at research grade to support direct sales and OEM supply opportunities.

**Food & Nutrition**

● **Recombinant Alpha-Lactalbumin:** A term sheet has been signed for the development of non-animal human alpha-lactalbumin for use in the infant nutrition market. Initial sampling of non-animal bovine alpha-lactalbumin for food and nutrition markets is in progress, and licensing discussions are underway with potential partners.

● **Non-Animal Dairy Enzymes (Inzymes Partnership):** Dyadic received a $250,000 milestone payment following the achievement of productivity improvements in Q3 2025. The first enzyme's scale-up is on track for a late 2025 launch, with additional enzyme candidates advancing as part of this partnership.

![](ex99-1_001.jpg)

**About Dyadic Applied BioSolutions**

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit <u>www.dyadic.com.</u>

**Safe Harbor Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic's control. These factors include, but are not limited to, the following: (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital needs; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) our ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.

Contact:

Dyadic International, Inc.

Ping Rawson

Chief Financial Officer

Phone: (561) 743-8333

Email: <u>ir@dyadic.com</u>